MK-677 – 25mg x 30ml
25mg per ml. 750mg total. Includes a graduated dropper. From the USA.
No questions asked return policy.
Independent Lab Testing
Purity is verified. Click here for more information.
Comodo SSL secure checkout.
Fast and Discrete Shipping
Same day USPS 1-3 day Priority Mail shipping for all orders placed before 6pm EST Monday through Friday.
Discount per Quantity
|Quantity||2 -3||4 -9||10 +|
- Reviews (8)
MK-677 is potent selective agonist of the ghrelin receptor and a growth hormone secretagogue causing significant elevation in growth hormone, IGF-1 and reduction in fat mass.
|Names:||Mk-677, MK-0677, L-163,191, Ibutamoren, Nutrobal
|Unit Size:||25mg x 30ml|
|CoA:||Certificate of Analysis for LOT#: 78909|
|Terms:||Research use only.|
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms.
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Growth hormone secretagogues: mechanism of action and use in aging.
Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).
Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.
Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.